Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 34838892.
- Also identified by DOI 10.1016/j.radonc.2021.11.012 and PMC identifier 8613981.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy is unknown. This prospective cohort study demonstrates that anti-SARS-CoV-2 spike antibody and neutralization titers are reduced in a subset of thoracic radiotherapy patients, possibly due to immunosuppressive conditions. Antibody testing may be useful to identify candidates for additional vaccine doses.
Medical subject headings
- COVID-19
- Neoplasms